Mangal Murti Enterprises Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Mangal Murti Enterprises Pharmaceutical Export Portfolio Dataset — 2 Products, $723.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mangal Murti Enterprises — Pharmaceutical Exporter Profile (2026) | 2 Products, $723.8K Trade | TransData Nexus

Mangal Murti Enterprises

Indian Pharmaceutical Exporter · Antihistamines & Allergy Specialist · $723.8K Total Trade · DGFT Verified

Mangal Murti Enterprises is an Indian pharmaceutical exporter with a total trade value of $723.8K across 2 products in 2 therapeutic categories. Based on 25 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Diphenhydramine ($542.4K), Codeine ($181.5K), .

Mangal Murti Enterprises — Export Portfolio & Destination Treemap

Mangal Murti Enterprises pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Mangal Murti Enterprises? — Company Overview & Market Position

Mangal Murti Enterprises is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2013, the company is headquartered in Agartala, Tripura, India. It operates as a proprietary firm under the leadership of CEO Siddhartha Nag. The company is registered with the Goods and Services Tax (GST) under the number 16ALOPN7431M1ZI. While specific revenue figures are not publicly disclosed, Mangal Murti Enterprises has demonstrated a consistent export performance, with a total export value of $724,000 USD across 25 shipments from 2022 to 2026. The company employs between 51 to 100 people, reflecting its substantial operational scale. For more information, the company maintains a website at www.mangalmurti.in.net.

What Does Mangal Murti Enterprises Export? — Product Portfolio Analysis

Top Products by Export Value

1Diphenhydramine$542.4K 2Codeine$181.5K

Product Portfolio — Top 2 by Export Value

Mangal Murti Enterprises exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Diphenhydramine	Antihistamines & Allergy	$542.4K	18	1.7%	11
2	Codeine	Analgesics & Antipyretics	$181.5K	7	0.2%	14

Mangal Murti Enterprises exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $723.8K. The top category is Antihistamines & Allergy (74.9% of portfolio), followed by Analgesics & Antipyretics (25.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Mangal Murti Enterprises — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Mangal Murti Enterprises operates manufacturing facilities in Agartala, Tripura, India. These facilities are equipped to produce a range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the company's export volume indicates a manufacturing capability that meets international demand. The facilities adhere to industry standards, ensuring the production of high-quality pharmaceutical products.

3Key Leadership

The leadership of Mangal Murti Enterprises is headed by CEO Siddhartha Nag, who has been instrumental in steering the company's growth and international expansion. Under his guidance, the company has achieved a total export value of $724,000 USD across 25 shipments from 2022 to 2026. Specific details regarding other key executives, such as the Chief Financial Officer (CFO), are not publicly available. The company's leadership is committed to maintaining high standards in pharmaceutical manufacturing and export operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Mangal Murti Enterprises Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Mangal Murti Enterprises has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's export data indicates shipments to various countries, suggesting compliance with international regulatory standards. For instance, the company has exported pharmaceutical products to Chad, Ghana, Benin, Cameroon, and Finland, indicating a diverse international footprint. While specific regulatory approvals and market access statuses are not detailed in the available data, the company's export activities imply adherence to the regulatory requirements of these markets.

2Emerging Markets

Mangal Murti Enterprises has made inroads into emerging markets in Africa, Latin America, and Southeast Asia. The company's export data reveals shipments to countries such as Chad, Ghana, Benin, Cameroon, and Finland, reflecting its strategic focus on expanding its global reach. While specific details regarding WHO prequalification or other certifications enabling access to these markets are not provided, the company's export activities suggest a commitment to meeting international standards and regulations.

3Geographic Strategy

Mangal Murti Enterprises — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Mangal Murti Enterprises' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data does not provide information on FDA approvals or compliance status. Given the company's export activities to various international markets, it is likely that Mangal Murti Enterprises adheres to the regulatory standards required by these markets. However, without explicit information, a comprehensive assessment of the company's FDA status cannot be made.

2WHO & EU GMP

Specific information regarding Mangal Murti Enterprises' World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The company's export data indicates shipments to various international markets, suggesting compliance with international quality standards. However, without explicit certifications or verifications, a detailed assessment of the company's adherence to WHO and EU GMP standards cannot be conducted.

3CDSCO & Indian Regulatory

Mangal Murti Enterprises — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical export sector, Mangal Murti Enterprises faces competition from several prominent companies, including Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, and Mylan Laboratories Limited. These competitors have significantly higher export values and a larger number of shipments, indicating a more substantial presence in the market. For example, Hetero Labs Limited reported an export value of $724.57 million across 9,722 shipments, while Mylan Laboratories Limited had an export value of $1,293.16 million across 16,278 shipments. In comparison, Mangal Murti Enterprises' export value of $724,000 across 25 shipments is modest. This suggests that while Mangal Murti Enterprises is a player in the pharmaceutical export market, it operates on a smaller scale compared to these industry leaders.

2Key Differentiators

Mangal Murti Enterprises' key differentiators include its specialization in finished pharmaceutical formulations and its focus on international markets. The company's export data indicates shipments to a diverse range of countries, reflecting its ability to meet the needs of various international markets. Additionally, the company's adherence to CDSCO regulations and its commitment to maintaining high-quality manufacturing practices underscore its dedication to product quality and regulatory compliance.

Buyer Due Diligence Brief — Evaluating Mangal Murti Enterprises as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Mangal Murti Enterprises has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $724,000 USD across 25 shipments from 2022 to 2026. The company's export data indicates shipments to various international markets, including Chad, Ghana, Benin, Cameroon, and Finland, reflecting its ability to meet the needs of diverse customers. The absence of publicly available records of regulatory actions or compliance issues further underscores the company's reliability as a supplier. However, specific details regarding the consistency and volume of exports are not provided, making it challenging to fully assess the company's reliability indicators.

2Certifications to Verify

Importers considering Mangal Murti Enterprises as a supplier should verify the following certifications to ensure product quality and regulatory compliance:

FDA Facility Registration: Confirm that the manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the company directly.

Frequently Asked Questions — Mangal Murti Enterprises

How many pharmaceutical products does Mangal Murti Enterprises export from India?

Mangal Murti Enterprises exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Diphenhydramine ($542.4K), Codeine ($181.5K). Total export value is $723.8K.

What is Mangal Murti Enterprises's total pharmaceutical export value?

Mangal Murti Enterprises's total pharmaceutical export value is $723.8K, based on 25 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Mangal Murti Enterprises cover?

Mangal Murti Enterprises exports across 2 therapeutic categories. The largest are Antihistamines & Allergy (74.9%, 1 products), Analgesics & Antipyretics (25.1%, 1 products).

Get Full Mangal Murti Enterprises Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.